Experimental models of its inhibition seem to reduce inflammation; on the other hand the human use of Bevacizumab, a humanized monoclonal antibody that inhibits VEGF-A, did not show positive effects on psoriasis and there are case reports of reactivation of PSO and PsA in course of treatment. This evidence concerns the gene VEGFA and psoriasis.